Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.

The Biochemical journal·2026

Same author

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026

Same author

In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion.

Blood advances·2026

Same author

A host defense role for Fibrinogen by direct binding of Clostridium botulinum C2 toxin.

Cellular and molecular life sciences : CMLS·2026

Same author

Production and characterization of gigastasin, a leech-derived inhibitor of complement and coagulation pathways.

Scientific reports·2026

Same author

New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

Journal of medicinal chemistry·2026

Same journal

Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases.

Frontiers in immunology·2026

Same journal

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer.

Frontiers in immunology·2026

Same journal

Modified treatment protocol for pediatric systemic lupus erythematosus-associated hemophagocytic lymphohistiocytosis with central nervous system involvement: a case report.

Frontiers in immunology·2026

Same journal

Exploratory characterization of IgG1/IgG4 glycosylation and monocyte-derived dendritic cell responses in esophageal squamous cell carcinoma.

Frontiers in immunology·2026

Same journal

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.

Frontiers in immunology·2026

Same journal

Cross-talk among novel programmed cell death pathways: a decisive network in renal ischemia-reperfusion injury.

Frontiers in immunology·2026

查看所有相关文章

Search research articles

相关实验视频

Updated: Jul 15, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

在微血管出血模型中,补充抑制可以在多个层面上降低静血反应.

Murielle Golomingi¹, Jessie Kohler¹, Christina Lamers²

¹Experimental Haemostasis Group, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland.

Frontiers in immunology

|September 29, 2023

概括

此摘要是机器生成的。

补体系统在血液静止中发挥作用,在血管损伤期间影响血块形成和血小板激活. 抑制补充通路显著影响这些过程,表明治疗潜力.

关键词:

与MBL相关的血清蛋白酶-2 (MASP-2)补充C1ss的补充C1s的补充补充 C3 补充 C3 补充补充 C5 补充 C5 补充补充因子D (FD) 是一个补充因子.互补系统是互补的系统.血液静止血液静止血液静止微流体学在微流体学方面

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关实验视频

Last Updated: Jul 15, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
血栓形成的原因之一是血栓形成.

背景情况:

静血,止血的过程,涉及血小板塞的形成和纤维素网状稳定通过凝血级联.
补体和凝血系统之间的相互作用可以加剧疾病中的血栓炎症.
补充剂在血管损伤后生理血液静止中的确切作用尚不清楚.

研究的目的:

调查补充成分和激活在机械血管损伤的静血反应中的作用.
探索各种补充抑制剂对凝块形成和血小板激活的影响.

主要方法:

使用了微血管出血模型与人体内皮细胞和全血.
引入机械伤害以模拟船舶损坏.
管理的补充抑制剂向莱克丁 (MASP-1,MASP-2),经典 (C1s),替代 (FD) 和常见 (C3,C5) 途径,以及三重抑制剂 (TriFu).
使用共聚焦显微镜实时量化纤维素沉积和血小板激活标记物 (CD62P).

主要成果:

抑制MASP-2或C1s的药物对纤维素形成没有显著影响.
替代途径抑制 (FD) 显著降低了血小板激活.
常见途径抑制剂 (C3,C5) 大大降低了纤维素的形成,C3抑制也降低了血小板激活.
三重抑制 (TriFu) 降低了纤维素形成和血小板激活.
TriFu,MASP-1和C3抑制剂对凝块形成表现出最强烈的影响.

结论:

补充系统的激活通过影响纤维素凝块形成和血小板激活来影响血静.
针对不同补充通路的调节器对血液静止有不同的影响.
补充-凝血相互作用可能已经演变为帮助血液静止,但可以促进病态状态中的血栓形成.